PDF herunterladen
Aktuelle Neurologie 2005; 32(1): 3-9
DOI: 10.1055/s-2004-834610
Neues in der Neurologie
© Georg Thieme Verlag KG Stuttgart · New York

Aktuelle Aspekte in der Pathogenese, Diagnostik und Therapie der Myasthenia gravis

Current Aspects in the Pathogenesis, Diagnosis, and Therapy of Myasthenia GravisS.  Jander1 , H.-P.  Hartung1
  • 1Neurologische Klinik, Universitätsklinikum Düsseldorf
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
27. Januar 2005 (online)

Auch verfügbar auf
    Lizenzen und Reprints

Zusammenfassung

In den letzten Jahren ist es bei der Myasthenia gravis zu einer Erweiterung des pathogenetischen Verständnisses und der therapeutischen Möglichkeiten gekommen. Neue klinische und immunologische Befunde legen eine differenzierte Klassifikation der Erkrankung nahe, die wichtige prognostische und therapeutische Implikationen hat. Viele der etablierten Therapien sind trotz unvollständiger Absicherung durch kontrollierte Studien von unbestrittener Wirksamkeit und haben die Prognose der Erkrankung drastisch verbessern können. In der präklinischen Entwicklung haben sich eine Reihe von antigenspezifischen Therapieansätze als wirksam erwiesen und könnten damit zukünftige Alternativen zur derzeit üblichen unspezifischen Immunsuppression darstellen.

Abstract

Recent years have witnessed significant advances in the pathogenetic understanding and therapy of autoimmune myasthenia gravis. New immunological and clinical data suggest a revised classification which has important prognostic and therapeutic implications. Although incompletely tested in controlled trials, immune-directed therapies are of undisputed efficacy and have dramatically improved the prognosis of myasthenic patients. Antigen-specific therapy has proven effective in preclinical animal studies and may offer future alternatives to nonspecific immunosuppression.

Literatur

  • 1 Drachman D B. Myasthenia gravis.  N Engl J Med. 1994;  330 1797-1810
    CrossrefPubMedGoogle Scholar
  • 2 Vincent A. Unravelling the pathogenesis of myasthenia gravis.  Nat Rev Immunol. 2002;  2 797-804
    CrossrefPubMedGoogle Scholar
  • 3 Richman D P, Agius M A. Treatment of autoimmune myasthenia gravis.  Neurology. 2003;  61 1652-1661
    CrossrefPubMedGoogle Scholar
  • 4 Keesey J C. Clinical evaluation and management of myasthenia gravis.  Muscle Nerve. 2004;  29 484-505
    CrossrefPubMedGoogle Scholar
  • 5 Lindstrom J M, Seybold M E, Lennon V A. et al . Antibody to acetylcholine receptor in myasthenia gravis. Prevalence, clinical correlates, and diagnostic value.  Neurology. 1976;  26 1054-1059
    CrossrefPubMedGoogle Scholar
  • 6 Toyka K V, Drachman D B, Griffin D E. et al . Myasthenia gravis. Study of humoral immune mechanisms by passive transfer to mice.  N Engl J Med. 1977;  296 125-131
    CrossrefPubMedGoogle Scholar
  • 7 Toyka K V, Heininger K. Acetylcholine receptor antibodies in the diagnosis of myasthenia gravis. Study of 406 confirmed cases.  Dtsch Med Wochenschr. 1986;  111 1435-1439
    PubMedGoogle Scholar
  • 8 Vincent A, Bowen J, Newsom-Davis J, McConville J. Seronegative generalised myasthenia gravis: clinical features, antibodies, and their targets.  Lancet Neurol. 2003;  2 99-106
    CrossrefPubMedGoogle Scholar
  • 9 Mossman S, Vincent A, Newsom-Davis J. Myasthenia gravis without acetylcholine-receptor antibody: a distinct disease entity.  Lancet. 1986;  1 116-119
    PubMedGoogle Scholar
  • 10 Mier A K, Havard C W. Diaphragmatic myasthenia in mother and child.  Postgrad Med J. 1985;  61 725-727
    PubMedGoogle Scholar
  • 11 Heckmatt J Z, Placzek M, Thompson A H. et al . An unusual case of neonatal myasthenia.  J Child Neurol. 1987;  2 63-66
    PubMedGoogle Scholar
  • 12 Burges J, Vincent A, Molenaar P C. et al . Passive transfer of seronegative myasthenia gravis to mice.  Muscle Nerve. 1994;  17 1393-1400
    PubMedGoogle Scholar
  • 13 Hoch W, McConville J, Helms S. et al . Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies.  Nat Med. 2001;  7 365-368
    CrossrefPubMedGoogle Scholar
  • 14 Evoli A, Tonali P A, Padua L. et al . Clinical correlates with anti-MuSK antibodies in generalized seronegative myasthenia gravis.  Brain. 2003;  126 2304-2311
    CrossrefPubMedGoogle Scholar
  • 15 McConville J, Farrugia M E, Beeson D. et al . Detection and characterization of MuSK antibodies in seronegative myasthenia gravis.  Ann Neurol. 2004;  55 580-584
    CrossrefPubMedGoogle Scholar
  • 16 Zhou L, McConville J, Chaudhry V. et al . Clinical comparison of muscle-specific tyrosine kinase (MuSK) antibody-positive and -negative myasthenic patients.  Muscle Nerve. 2004;  30 55-60
    CrossrefPubMedGoogle Scholar
  • 17 Sanders D B, El Salem S, Massey J M. et al . Clinical aspects of MuSK antibody positive seronegative MG.  Neurology. 2003;  60 1978-1980
    CrossrefPubMedGoogle Scholar
  • 18 Scuderi F, Marino M, Colonna L. et al . Anti-p110 autoantibodies identify a subtype of „seronegative” myasthenia gravis with prominent oculobulbar involvement.  Lab Invest. 2002;  82 1139-1146
    PubMedGoogle Scholar
  • 19 Abicht A, Lochmüller H. What's in the serum of seronegative MG and LEMS? MuSK et al.  Neurology. 2002;  59 1672-1673
    PubMedGoogle Scholar
  • 20 Sahashi K, Engel A G, Lambert E H, Howard Jr F M. Ultrastructural localization of the terminal and lytic ninth complement component (C9) at the motor end-plate in myasthenia gravis.  J Neuropathol Exp Neurol. 1980;  39 160-172
    PubMedGoogle Scholar
  • 21 Vincent A, McConville J, Farrugia M E. et al . Antibodies in myasthenia gravis and related disorders.  Ann N Y Acad Sci. 2003;  998 324-335
    CrossrefPubMedGoogle Scholar
  • 22 Liyanage Y, Hoch W, Beeson D, Vincent A. The agrin/muscle-specific kinase pathway: new targets for autoimmune and genetic disorders at the neuromuscular junction.  Muscle Nerve. 2002;  25 4-16
    PubMedGoogle Scholar
  • 23 Selcen D, Fukuda T, Shen X M, Engel A G. Are MuSK antibodies the primary cause of myasthenic symptoms?.  Neurology. 2004;  62 1945-1950
    PubMedGoogle Scholar
  • 24 Lindstrom J. Is „seronegative” MG explained by autoantibodies to MuSK?.  Neurology. 2004;  62 1920-1921
    PubMedGoogle Scholar
  • 25 Agius M A, Zhu S, Kirvan C A. et al . Rapsyn antibodies in myasthenia gravis.  Ann N Y Acad Sci. 1998;  841 516-521
    PubMedGoogle Scholar
  • 26 Baets M De, Stassen M, Losen M. et al . Immunoregulation in experimental autoimmune myasthenia gravis - about T cells, antibodies, and endplates.  Ann N Y Acad Sci. 2003;  998 308-317
    CrossrefPubMedGoogle Scholar
  • 27 Aarli J A, Stefansson K, Marton L S, Wollmann R L. Patients with myasthenia gravis and thymoma have in their sera IgG autoantibodies against titin.  Clin Exp Immunol. 1990;  82 284-288
    PubMedGoogle Scholar
  • 28 Romi F, Skeie G O, Aarli J A, Gilhus N E. Muscle autoantibodies in subgroups of myasthenia gravis patients.  J Neurol. 2000;  247 369-375
    PubMedGoogle Scholar
  • 29 Voltz R D, Albrich W C, Nagele A. et al . Paraneoplastic myasthenia gravis: detection of anti-MGT30 (titin) antibodies predicts thymic epithelial tumor.  Neurology. 1997;  49 1454-1457
    PubMedGoogle Scholar
  • 30 Buckley C, Newsom-Davis J, Willcox N, Vincent A. Do titin and cytokine antibodies in MG patients predict thymoma or thymoma recurrence?.  Neurology. 2001;  57 1579-1582
    PubMedGoogle Scholar
  • 31 Yamamoto A M, Gajdos P, Eymard B. et al . Anti-titin antibodies in myasthenia gravis: tight association with thymoma and heterogeneity of nonthymoma patients.  Arch Neurol. 2001;  58 885-890
    CrossrefPubMedGoogle Scholar
  • 32 Compston D A, Vincent A, Newsom-Davis J, Batchelor J R. Clinical, pathological, HLA antigen and immunological evidence for disease heterogeneity in myasthenia gravis.  Brain. 1980;  103 579-601
    CrossrefPubMedGoogle Scholar
  • 33 Agius M A, Richman D P, Fairclough R H. et al . Three forms of immune myasthenia.  Ann N Y Acad Sci. 2003;  998 453-456
    CrossrefPubMedGoogle Scholar
  • 34 Gronseth G S, Barohn R J. Practice parameter: thymectomy for autoimmune myasthenia gravis (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology.  Neurology. 2000;  55 7-15
    CrossrefPubMedGoogle Scholar
  • 35 Romi F, Gilhus N E, Varhaug J E. et al . Thymectomy and anti-muscle autoantibodies in late-onset myasthenia gravis.  Eur J Neurol. 2002;  9 55-61
    PubMedGoogle Scholar
  • 36 Graves M, Katz J S. Myasthenia gravis.  Curr Treat Options Neurol. 2004;  6 163-171
    PubMedGoogle Scholar
  • 37 Palace J, Newsom-Davis J, Lecky B. A randomized double-blind trial of prednisolone alone or with azathioprine in myasthenia gravis. Myasthenia Gravis Study Group.  Neurology. 1998;  50 1778-1783
    CrossrefPubMedGoogle Scholar
  • 38 Hohlfeld R, Toyka K V, Besinger U A. et al . Myasthenia gravis: reactivation of clinical disease and of autoimmune factors after discontinuation of long-term azathioprine.  Ann Neurol. 1985;  17 238-242
    CrossrefPubMedGoogle Scholar
  • 39 Michels M, Hohlfeld R, Hartung H P. et al . Myasthenia gravis: discontinuation of long-term azathioprine.  Ann Neurol. 1988;  24 798
    CrossrefPubMedGoogle Scholar
  • 40 Tindall R S, Rollins J A, Phillips J T. et al . Preliminary results of a double-blind, randomized, placebo-controlled trial of cyclosporine in myasthenia gravis.  N Engl J Med. 1987;  316 719-724
    CrossrefPubMedGoogle Scholar
  • 41 Behrend M, Lueck R, Pichlmayr R. Long-term experience with mycofenolate mofetil in the prevention of renal allograft rejection.  Transplant Proc. 1997;  29 2927-2929
    CrossrefPubMedGoogle Scholar
  • 42 Allison A C, Kowalski W J, Muller C D, Eugui E M. Mechanisms of action of mycophenolic acid.  Ann N Y Acad Sci. 1993;  696 63-87
    PubMedGoogle Scholar
  • 43 Hauser R A, Malek A R, Rosen R. Successful treatment of a patient with severe refractory myasthenia gravis using mycophenolate mofetil.  Neurology. 1998;  51 912-913
    PubMedGoogle Scholar
  • 44 Chaudhry V, Cornblath D R, Griffin J W. et al . Mycophenolate mofetil: a safe and promising immunosuppressant in neuromuscular diseases.  Neurology. 2000;  56 94-96
    PubMedGoogle Scholar
  • 45 Ciafaloni E, Massey J M, Tucker-Lipscomb B, Sanders D B. Mycophenolate mofetil for myasthenia gravis: an open-label pilot study.  Neurology. 2000;  56 97-99
    PubMedGoogle Scholar
  • 46 Meriggioli M N, Rowin J. Treatment of myasthenia gravis with mycophenolate mofetil: a case report.  Muscle Nerve. 2000;  23 1287-1289
    PubMedGoogle Scholar
  • 47 Mowzoon N, Sussman A, Bradley W G. Mycophenolate (CellCept) treatment of myasthenia gravis, chronic inflammatory polyneuropathy and inclusion body myositis.  J Neurol Sci. 2001;  185 119-122
    CrossrefPubMedGoogle Scholar
  • 48 Schneider C, Gold R, Reiners K, Toyka K V. Mycophenolate mofetil in the therapy of severe myasthenia gravis.  Eur Neurol. 2001;  46 79-82
    CrossrefPubMedGoogle Scholar
  • 49 Meriggioli M N, Ciafaloni E, Al Hayk K A. et al . Mycophenolate mofetil for myasthenia gravis: an analysis of efficacy, safety, and tolerability.  Neurology. 2003;  61 1438-1440
    CrossrefPubMedGoogle Scholar
  • 50 Meriggioli M N, Rowin J, Richman J G, Leurgans S. Mycophenolate mofetil for myasthenia gravis: a double-blind, placebo-controlled pilot study.  Ann N Y Acad Sci. 2003;  998 494-499
    CrossrefPubMedGoogle Scholar
  • 51 Feo L G de, Schottlender J, Martelli N A, Molfino N A. Use of intravenous pulsed cyclophosphamide in severe, generalized myasthenia gravis.  Muscle Nerve. 2002;  26 31-36
    CrossrefPubMedGoogle Scholar
  • 52 Drachman D B, Jones R J, Brodsky R A. Treatment of refractory myasthenia: „Rebooting” with high-dose cyclophosphamide.  Ann Neurol. 2003;  53 29-34
    CrossrefPubMedGoogle Scholar
  • 53 Gladstone D E, Brannagan III T H, Schwartzman R J. et al . High dose cyclophosphamide for severe refractory myasthenia gravis.  J Neurol Neurosurg Psychiatry. 2004;  75 789-791
    PubMedGoogle Scholar
  • 54 Zaja F, Russo D, Fuga G. et al . Rituximab for myasthenia gravis developing after bone marrow transplant.  Neurology. 2000;  55 1062-1063
    PubMedGoogle Scholar
  • 55 Wylam M E, Anderson P M, Kuntz N L, Rodriguez V. Successful treatment of refractory myasthenia gravis using rituximab: a pediatric case report.  J Pediatr. 2003;  143 674-677
    CrossrefPubMedGoogle Scholar
  • 56 Gajra A, Vajpayee N, Grethlein S J. Response of myasthenia gravis to rituximab in a patient with non-Hodgkin lymphoma.  Am J Hematol. 2004;  77 196-197
    CrossrefPubMedGoogle Scholar
  • 57 Gajdos P, Chevret S, Clair B. et al . Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis. Myasthenia Gravis Clinical Study Group.  Ann Neurol. 1997;  41 789-796
    CrossrefPubMedGoogle Scholar
  • 58 Achiron A, Barak Y, Miron S, Sarova-Pinhas I. Immunoglobulin treatment in refractory Myasthenia gravis.  Muscle Nerve. 2000;  23 551-555
    CrossrefPubMedGoogle Scholar
  • 59 Wolfe G I, Barohn R J, Foster B M. et al . Randomized, controlled trial of intravenous immunoglobulin in myasthenia gravis.  Muscle Nerve. 2002;  26 549-552
    CrossrefPubMedGoogle Scholar
  • 60 Gajdos P, Chevret S, Toyka K. Plasma exchange for myasthenia gravis. Cochrane Database Syst Rev 2002 CD002275
    Google Scholar
  • 61 Gajdos P, Chevret S, Toyka K. Intravenous immunoglobulin for myasthenia gravis (Cochrane Review). Cochrane Database Syst Rev 2003 CD002277
    Google Scholar
  • 62 Dalakas M C. Intravenous immunoglobulin in autoimmune neuromuscular diseases.  JAMA. 2004;  291 2367-2375
    CrossrefPubMedGoogle Scholar
  • 63 Yeh J H, Chiu H C. Comparison between double-filtration plasmapheresis and immunoadsorption plasmapheresis in the treatment of patients with myasthenia gravis.  J Neurol. 2000;  247 510-513
    CrossrefPubMedGoogle Scholar
  • 64 Flachenecker P, Taleghani B M, Gold R. et al . Treatment of severe myasthenia gravis with protein A immunoadsorption and cyclophosphamide.  Transfus Sci. 1998;  19, Suppl 43-46
    PubMedGoogle Scholar
  • 65 Psaridi-Linardaki L, Mamalaki A, Tzartos S J. Future therapeutic strategies in autoimmune myasthenia gravis.  Ann N Y Acad Sci. 2003;  998 539-548
    CrossrefPubMedGoogle Scholar
  • 66 McQuillen M P, Leone M G. A treatment carol: thymectomy revisited.  Neurology. 1977;  27 1103-1106
    CrossrefPubMedGoogle Scholar
  • 67 Buckingham J M, Howard Jr F M, Bernatz P E. et al . The value of thymectomy in myasthenia gravis: a computer-assisted matched study.  Ann Surg. 1976;  184 453-458
    PubMedGoogle Scholar
  • 68 Yim A P, Kay R L, Ho J K. Video-assisted thoracoscopic thymectomy for myasthenia gravis.  Chest. 1995;  108 1440-1443
    CrossrefPubMedGoogle Scholar
  • 69 Ruckert J C, Gellert K, Muller J M. Operative technique for thoracoscopic thymectomy.  Surg Endosc. 1999;  13 943-946
    CrossrefPubMedGoogle Scholar
  • 70 Wright G M, Barnett S, Clarke C P. Video-assisted thoracoscopic thymectomy for myasthenia gravis.  Intern Med J. 2002;  32 367-371
    CrossrefPubMedGoogle Scholar
  • 71 Mantegazza R, Baggi F, Bernasconi P. et al . Video-assisted thoracoscopic extended thymectomy and extended transsternal thymectomy (T-3b) in non-thymomatous myasthenia gravis patients: remission after 6 years of follow-up.  J Neurol Sci. 2003;  212 31-36
    CrossrefPubMedGoogle Scholar
  • 72 Ruckert J C, Sobel H K, Gohring S. et al . Matched-pair comparison of three different approaches for thymectomy in myasthenia gravis.  Surg Endosc. 2003;  17 711-715
    CrossrefPubMedGoogle Scholar
  • 73 Zielinski M, Kuzdzal J, Szlubowski A, Soja J. Transcervical-subxiphoid-videothoracoscopic „maximal” thymectomy - operative technique and early results.  Ann Thorac Surg. 2004;  78 404-409
    CrossrefPubMedGoogle Scholar
  • 74 Zielinski M, Kuzdzal J, Szlubowski A, Soja J. Comparison of late results of basic transsternal and extended transsternal thymectomies in the treatment of myasthenia gravis.  Ann Thorac Surg. 2004;  78 253-258
    CrossrefPubMedGoogle Scholar
  • 75 Lanska D J. Indications for thymectomy in myasthenia gravis.  Neurology. 1990;  40 1828-1829
    CrossrefPubMedGoogle Scholar
  • 76 Wolfe G I, Kaminski H J, Jaretzki III A. et al . Development of a thymectomy trial in nonthymomatous myasthenia gravis patients receiving immunosuppressive therapy.  Ann N Y Acad Sci. 2003;  998 473-480
    CrossrefPubMedGoogle Scholar
  • 77 Abbas A K, Murphy K M, Sher A. Functional diversity of helper T lymphocytes.  Nature. 1996;  383 787-793
    CrossrefPubMedGoogle Scholar
  • 78 Balasa B, Sarvetnick N. Is pathogenic humoral autoimmunity a Th1 response? Lessons from (for) myasthenia gravis.  Immunol Today. 2000;  21 19-23
    CrossrefPubMedGoogle Scholar
  • 79 Link H, Olsson O, Sun J. et al . Acetylcholine receptor-reactive T and B cells in myasthenia gravis and controls.  J Clin Invest. 1991;  87 2191-2195
    PubMedGoogle Scholar
  • 80 Balasa B, Deng C, Lee J. et al . Interferon gamma (IFN-gamma) is necessary for the genesis of acetylcholine receptor-induced clinical experimental autoimmune myasthenia gravis in mice.  J Exp Med. 1997;  186 385-391
    CrossrefPubMedGoogle Scholar
  • 81 Balasa B, Deng C, Lee J. et al . The Th2 cytokine IL-4 is not required for the progression of antibody-dependent autoimmune myasthenia gravis.  J Immunol. 1998;  161 2856-2862
    PubMedGoogle Scholar
  • 82 Moiola L, Galbiati F, Martino G. et al . IL-12 is involved in the induction of experimental autoimmune myasthenia gravis, an antibody-mediated disease.  Eur J Immunol. 1998;  28 2487-2497
    CrossrefPubMedGoogle Scholar
  • 83 Shi F D, Wang H B, Li H. et al . Natural killer cells determine the outcome of B cell-mediated autoimmunity.  Nat Immunol. 2000;  1 245-251
    CrossrefPubMedGoogle Scholar
  • 84 Im S H, Barchan D, Maiti P K. et al . Suppression of experimental myasthenia gravis, a B cell-mediated autoimmune disease, by blockade of IL-18.  FASEB J. 2001;  15 2140-2148
    CrossrefPubMedGoogle Scholar
  • 85 Jander S, Stoll G. Increased serum levels of the interferon-gamma-inducing cytokine interleukin-18 in myasthenia gravis.  Neurology. 2002;  59 287-289
    PubMedGoogle Scholar
  • 86 Pachner A R. Antigen-specific immunotherapy in myasthenia gravis: failed promise and new hope.  J Neuroimmunol. 2004;  152 vii-viii
    CrossrefPubMedGoogle Scholar
  • 87 Sela M, Mozes E. Therapeutic vaccines in autoimmunity.  Proc Natl Acad Sci U S A. 2004;  101, Suppl 2 14586-14592
    CrossrefPubMedGoogle Scholar
  • 88 Katz-Levy Y, Kirshner S L, Sela M, Mozes E. Inhibition of T-cell reactivity to myasthenogenic epitopes of the human acetylcholine receptor by synthetic analogs.  Proc Natl Acad Sci U S A. 1993;  90 7000-7004
    PubMedGoogle Scholar
  • 89 Nicolle M W, Nag B, Sharma S D. et al . Specific tolerance to an acetylcholine receptor epitope induced in vitro in myasthenia gravis CD4+ lymphocytes by soluble major histocompatibility complex class II-peptide complexes.  J Clin Invest. 1994;  93 1361-1369
    PubMedGoogle Scholar
  • 90 Im S H, Barchan D, Fuchs S, Souroujon M C. Suppression of ongoing experimental myasthenia by oral treatment with an acetylcholine receptor recombinant fragment.  J Clin Invest. 1999;  104 1723-1730
    PubMedGoogle Scholar
  • 91 Paas-Rozner M, Dayan M, Paas Y. et al . Oral administration of a dual analog of two myasthenogenic T cell epitopes down-regulates experimental autoimmune myasthenia gravis in mice.  Proc Natl Acad Sci U S A. 2000;  97 2168-2173
    CrossrefPubMedGoogle Scholar
  • 92 Souroujon M C, Maiti P K, Feferman T. et al . Suppression of myasthenia gravis by antigen-specific mucosal tolerance and modulation of cytokines and costimulatory factors.  Ann N Y Acad Sci. 2003;  998 533-536
    CrossrefPubMedGoogle Scholar
  • 93 Drachman D B, Wu J M, Miagkov A. et al . Specific immunotherapy of experimental myasthenia by genetically engineered APCs: the „guided missile” strategy.  Ann N Y Acad Sci. 2003;  998 520-532
    CrossrefPubMedGoogle Scholar
  • 94 Paas-Rozner M, Sela M, Mozes E. The nature of the active suppression of responses associated with experimental autoimmune myasthenia gravis by a dual altered peptide ligand administered by different routes.  Proc Natl Acad Sci U S A. 2001;  98 12642-12647
    CrossrefPubMedGoogle Scholar
  • 95 Dayan M, Sthoeger Z, Neiman A. et al . Immunomodulation by a dual altered peptide ligand of autoreactive responses to the acetylcholine receptor of peripheral blood lymphocytes of patients with myasthenia gravis.  Hum Immunol. 2004;  65 571-577
    CrossrefPubMedGoogle Scholar

Priv.-Doz. Dr. med. Sebastian Jander

Neurologische Klinik · Universitätsklinikum Düsseldorf · Heinrich-Heine-Universität

Moorenstraße 5

40225 Düsseldorf

eMail: jander@uni-duesseldorf.de

      >